Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 323 KB, PDF-dokument

  • Jon Salmanton-García
  • Francesco Marchesi
  • Yavuz M. Bilgin
  • Jens Van Praet
  • Julio Dávila-Valls
  • Sonia Martín-Pérez
  • Jorge Labrador
  • Jaap Van Doesum
  • Iker Falces-Romero
  • Francesca Farina
  • Martin Schönlein
  • Mathilde Chanut
  • Verena Petzer
  • Ildefonso Espigado
  • Michelina Dargenio
  • Avinash Aujayeb
  • Uluhan Sili
  • Laura Serrano
  • László Imre Pinczés
  • Nick De Jonge
  • Andrés Soto-Silva
  • Caterina Buquicchio
  • Lucia Prezioso
  • Monia Marchetti
  • Stef Meers
  • Alessandro Busca
  • Paolo Corradini
  • Martin Hoenigl
  • Philipp Koehler
  • Laman Rahimli
  • Gökçe Melis Çolak
  • Elena Arellano
  • Dominik Wolf
  • Stefanie Gräfe
  • Emanuele Ammatuna
  • Caroline Berg Venemyr
  • Oliver A. Cornely
  • Livio Pagano
OriginalsprogEngelsk
TidsskriftHemaSphere
Vol/bind6
Udgave nummer11
Sider (fra-til)E789
ISSN2572-9241
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223). The funder of the study had no role in study design, data analysis, interpretation, or writing of the report. All authors had full access to the data and had final responsibility for the decision to submit for publication.

ID: 341015599